More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

Recommendation based on the Phase 2 TRANSCEND FL study in which 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving complete response Across clinical trials, Breyanzi has ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy ... large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma ...

Brandow, who learned she had stage 4 lymphoma in 2020 after giving birth to her younger son, wants to lift barriers to health ...

Cancer survivor Zoe Plastiras hopes her message provides some reassurance by highlighting advances in cancer treatment.